Aptose Biosciences' price target raised to $6 due to focus on triple first-line path for AML

From Yahoo Finance: 2025-03-29 12:00:00

H.C. Wainwright analyst raised Aptose Biosciences’ price target to $6, citing focus on triple first-line path for AML. The firm also adjusted estimate of fully diluted share count post reverse split and projected launch year for first-line AML in the U.S. as 2030. Buy rating maintained.

(Source: TheFly)

For more information on top-performing stocks, visit TipRanks.

(Source: TipRanks)

Find out more about Aptose Biosciences on TipRanks.

(Source: TipRanks)

Read more: Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright